Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Product Development

Tempus aims for precision in complexity

With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibition of cancer cell NDUFS4 for antitumor immunity

BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibiting P4HA1 for antitumor immunity

BioCentury | Feb 20, 2025
Product Development

Solid produces best-in-class biomarker data among DMD gene therapies

BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Feb 18, 2025
Product Development

Remaking Roche

How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting CD28 inside tumor cells for TNBC

BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting ZDHHC3 for HCC antitumor immunity

BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting SLC13A3 for immunotherapy-resistant cancer

BioCentury | Jan 18, 2025
Product Development

2025 catalysts: Bispecifics poised to enter new era

Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Dec 19, 2024
Emerging Company Profile

Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2

Newco, led by ex-Seagen CEO Epstein, announces $140M series A
Items per page:
1 - 10 of 1305